These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16303884)

  • 21. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.
    Carlquist JF; Anderson JL
    Circulation; 2011 Dec; 124(23):2554-9. PubMed ID: 22144632
    [No Abstract]   [Full Text] [Related]  

  • 23. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Possible application of pharmacogenomics to warfarin therapy].
    Murata M
    Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
    Avery PJ; Jorgensen A; Hamberg AK; Wadelius M; Pirmohamed M; Kamali F;
    Clin Pharmacol Ther; 2011 Nov; 90(5):701-6. PubMed ID: 22012312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?
    Baglin TP
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):656-7. PubMed ID: 16258463
    [No Abstract]   [Full Text] [Related]  

  • 28. Warfarin and pharmacogenomic testing: what would Pascal do?
    Teagarden JR
    Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943
    [No Abstract]   [Full Text] [Related]  

  • 29. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 32. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
    Schwarz UI; Stein CM
    Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.
    Franchini M; Mengoli C; Cruciani M; Bonfanti C; Mannucci PM
    J Thromb Haemost; 2014 Sep; 12(9):1480-7. PubMed ID: 25040440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
    Cavallari LH; Nutescu EA
    Clin Pharmacol Ther; 2014 Jul; 96(1):22-4. PubMed ID: 24942399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment.
    Bertola JP; Mazoyer E; Bergmann JF; Drouet L; Simoneau G; Mahé I
    Thromb Res; 2003 Mar; 109(5-6):287-91. PubMed ID: 12818252
    [No Abstract]   [Full Text] [Related]  

  • 37. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
    Siguret V; Pautas E; Gouin-Thibault I
    Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
    Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
    J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.